Get the Stockscreener App
395.86
0.14%
0.605
Vertex Pharmaceuticals Inc stock is traded at $395.86, with a volume of 645.09K.
It is up +0.14% in the last 24 hours and up +7.99% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$395.25
Open:
$395.01
24h Volume:
645.09K
Relative Volume:
0.40
Market Cap:
$101.49B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
28.30
EPS:
13.99
Net Cash Flow:
$3.50B
1W Performance:
-1.29%
1M Performance:
+7.99%
6M Performance:
-18.94%
1Y Performance:
-15.98%
1-Day Range:
$391.71
$397.31
1-Week Range:
$390.98
$402.74
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
395.86 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.19 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.62 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
766.85 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
349.89 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Top Biotech Stocks To Watch NowSeptember 7th - MarketBeat
Is There Enough Volume to Lift Vertex Pharmaceuticals IncorporatedIPO Watch & Stepwise Trade Signal Guides - beatles.ru
Vertex predicted to remain front and center of modest CF market growth - The Pharma Letter
Is Vertex Pharmaceuticals Stock Underperforming the S&P 500? - MSN
2025 Vertex Foundation Scholarship recipients: Real stories and reimagined futures - Vertex Pharmaceuticals
Is Vertex Pharmaceuticals Stock Underperforming The S&P 500? - Barchart.com
Vertex Pharmaceuticals and Enlaza Therapeutics Partner in $2.4 Billion Deal to Develop Autoimmune Disease Therapies - geneonline.com
Enlaza Therapeutics and Vertex Pharmaceuticals Partner in $2.4 Billion Deal to Develop Autoimmune Disease Therapies - geneonline.com
Is Vertex Pharmaceuticals Incorporated still worth holding after the dip2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Relative strength of Vertex Pharmaceuticals Incorporated in sector analysisPortfolio Return Report & Real-Time Market Sentiment Alerts - Newser
Volatility clustering patterns for Vertex Pharmaceuticals IncorporatedRate Hike & High Yield Equity Trading Tips - Newser
Vertex Pharma, Enlaza sign R&D pact worth up to $2B plus equity - MSN
Is Vertex Pharmaceuticals Incorporated stock reversal real or fakeWeekly Earnings Recap & Long-Term Investment Growth Plans - Newser
Is Vertex Pharmaceuticals Incorporated attractive for institutional investorsMarket Weekly Review & Accurate Buy Signal Notifications - خودرو بانک
Using Bollinger Bands to evaluate Vertex Pharmaceuticals Incorporated2025 Trade Ideas & Reliable Intraday Trade Plans - Newser
Is Vertex Pharmaceuticals Incorporated meeting your algorithmic filter criteriaDip Buying & High Accuracy Swing Entry Alerts - Newser
Is Vertex Pharmaceuticals Incorporated part of any major indexJuly 2025 Selloffs & AI Powered Buy/Sell Recommendations - خودرو بانک
Is Vertex Pharmaceuticals Incorporated in a bullish channelQuarterly Performance Summary & AI Powered Market Entry Strategies - خودرو بانک
Automated trading signals detected on Vertex Pharmaceuticals IncorporatedWeekly Market Report & Reliable Price Breakout Signals - Newser
What is Vertex Pharmaceuticals Incorporated s revenue forecastEarnings Beat & Real-Time Buy Signal Alerts - خودرو بانک
Enlaza Therapeutics and Vertex Pharmaceuticals Announce $2.4 Billion Collaboration to Develop Autoimmune Disease Therapies - geneonline.com
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysisRecession Risk & Weekly Momentum Stock Picks - Newser
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzedJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Signals and Key Fundamentals to Watch - AInvest
Is Vertex Pharmaceuticals Incorporated subject to activist investor interest2025 Pullback Review & Safe Entry Momentum Stock Tips - خودرو بانک
Hedge Fund Moves: Is Vertex Pharmaceuticals Incorporated stock trending bullishJuly 2025 Closing Moves & Fast Moving Stock Watchlists - خودرو بانک
Why This Biotech Company Could Be a Growth Stock Powerhouse - Mitrade
Why is Vertex Pharmaceuticals Incorporated stock going upQuarterly Growth Report & Low Volatility Stock Suggestions - خودرو بانک
Vertex ends development of alpha-1 antitrypsin deficiency drug VX-814 - FirstWord Pharma
How to monitor Vertex Pharmaceuticals Incorporated with trend dashboardsJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Enlaza Therapeutics Forms $2.4 Billion Collaboration with Vertex Pharmaceuticals - Pharmaceutical Executive
Vertex Pharmaceuticals: Raymond James Initiates Coverage with Market Perform Rating - AInvest
Transcript : Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 11 - MarketScreener
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? - sg.finance.yahoo.com
Enlaza takes the helm in a $2B+ Vertex deal - BioWorld MedTech
Why Vertex Pharmaceuticals (VRTX) Is on Loomis Sayles Growth Fund’s Detractors List - AInvest
Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List - Insider Monkey
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途牛牛
Top chart patterns to watch in Vertex Pharmaceuticals IncorporatedWeekly Trade Report & Fast Gaining Stock Reports - Newser
Vertex teams with Enlaza to expand gene therapy options - The Pharma Letter
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Tools to assess Vertex Pharmaceuticals Incorporated’s risk profileGap Up & Weekly Market Pulse Updates - Newser
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Sentiment analysis tools applied to Vertex Pharmaceuticals Incorporated2025 Market WrapUp & Safe Entry Zone Tips - Newser
Does Vertex Pharmaceuticals Incorporated meet Warren Buffett’s criteriaQuarterly Trade Review & Growth-Oriented Investment Plans - khodrobank.com
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Vertex Stock Surges 2.55% on 44% Volume Spike to $740M Ranking 135th as $2B Collaboration with Enlaza Drives Strategic Expansion - AInvest
Vertex locks on to $2B covalent biologics deal with Enlaza - FirstWord Pharma
Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Fundamental Recap & Safe Entry Zone Tips - khodrobank.com
Enlaza Therapeutics strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers - MarketScreener
Vertex Pharmaceuticals Partners with Enlaza Therapeutics in $45 Million Deal to Develop Autoimmune and Gene-Editing Therapies - geneonline.com
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):